CV Technologies/HerbTech
This article was originally published in The Tan Sheet
Executive Summary
Merger of firms awaits shareholder and regulatory approval; shareholder meetings for both firms scheduled for June 25. The Canadian biopharmaceutical firm CVT uses its ChemBioPrint technology to develop pharmaceuticals and dietary supplements derived from plants and other natural substances. The firm has six patents pending. Phase II trials are under way for the first of the formulations, a product intended to treat hypertension. A pilot study on a product to treat Attention-Deficit Hyperactivity Disorder has finished. HerbTech, in conjunction with CVT, extracts active ingredients of herbs and other materials. The firm sells FX and MegaHerb supplements in the U.S., Canada, Brazil and Southeast Asia...